Latest Data on Penumbra’s CAVT Technology to Be Presented at SIR 2025: STRIDE, STRIKE-PE, and More

New data from the ongoing STRIKE-PE and STRIDE studies will be presented at the Society of Interventional Radiology (SIR) Annual Scientific Meeting taking place March 29th through April 2nd in Nashville, Tennessee. The latest interim results of these multi-centered, prospective studies continue to build further evidence to support the benefits of computer assisted vacuum thrombectomy (CAVT) technology to address pulmonary embolism (PE) and acute limb ischemia (ALI), respectively. Additionally, new market access findings will highlight the impact of CAVT on overall resource use in the healthcare setting.

“These latest findings will continue to demonstrate the positive impact of CAVT across patient care and the healthcare setting,” said James F. Benenati, M.D., FSIR, chief medical officer at Penumbra. “Our focus is to build a robust library of clinical evidence to further establish CAVT as a valuable frontline option for thrombus management — not only centered on safety and efficacy, but also demonstrating the potential value it brings to hospitals in an effort to decrease the overall cost of care.”

Presentation Schedule

Sunday, March 30, 2025

• 3:00 pm CT: Outcomes Comparing Acute Pulmonary Embolism Patients With vs Without Syncope and Treated with Computer Assisted Vacuum Thrombectomy: STRIKE-PE Interim Analysis
  Presenter: John Moriarty, M.D., UCLA Medical Center, Los Angeles, CA, US
• 3:09 pm CT: Computer Assisted Vacuum Thrombectomy with Lightning Flash for Acute Pulmonary Embolism Patients: STRIKE-PE Analysis of 164 Patients
  Presenter: Brian Schiro, M.D., Miami Vascular Specialists, Baptist Hospital, Miami, FL, US
• 3:45 pm CT: STRIDE Study Subgroup Analyses: Using Mechanical Aspiration Thrombectomy for In-stent Thrombosis Versus Native-vessel Thrombosis Yields Similar Outcomes
  Presenter: Alex Powell, M.D., Miami Vascular Specialists, Baptist Hospital, Miami, FL, US

Monday, March 31, 2025

• 3:36 pm CT: Market Access & Health Economics: Computer-Assisted Vacuum Thrombectomy vs. Anticoagulation for Ilio-Femoral [Thrombus]: A comparative analysis of hospital and post-hospital outcomes
  Presenter: Kush Desai, M.D., Northwestern University, Chicago, IL, US
• 4:12 pm CT: STRIKE-PE – Effect of sPESI Score (0 vs ≥1) on the Outcomes of Acute Pulmonary Embolism Patients Treated with Computer Assisted Vacuum Thrombectomy
  Presenter: John Moriarty, M.D., UCLA Medical Center, Los Angeles, CA, US
• 4:21 pm CT: [Therapy] Outcomes and Healthcare Resource Utilization in Computer Assisted Vacuum Thrombectomy versus Open Embolectomy: The THRIVE Study
  Presenter: Bulent Arslan, M.D., Rush University, Chicago, IL, US

Tuesday, April 1, 202

• 3:00 pm CT: Improved Right Ventricle/Left Ventricle Ratio and Functional Outcomes After Computer Assisted Vacuum Thrombectomy for Treatment of Acute Pulmonary Embolism: Analysis of the First 450 STRIKE-PE Patients
  Presenter: John Moriarty, M.D., UCLA Medical Center, Los Angeles, CA, US

More about these studies:

• STRIKE-PE is a prospective, international, multicenter study evaluating real-world safety, performance, and long-term quality-of-life outcomes of CAVT with Penumbra’s Indigo® Aspiration System for the treatment of PE. Learn more about the STRIKE-PE Study: https://www.penumbrainc.com/strike-pe-study/
• The STRIDE study is an international, multi-center, prospective, single-arm study using mechanical thrombectomy with Indigo Aspiration System as frontline use for lower extremity acute limb ischemia. Learn more about the STRIDE Study: https://www.penumbrainc.com/stride-study/
• The Market Access & Health Economics study is a retrospective observational comparative analysis of deidentified data from inpatient adults to describe and compare healthcare resource use and outcomes among patients with ilio-femoral thrombus who underwent CAVT or anticoagulation in the United States.
• The THRIVE Study, another market access and health economics examination, is a retrospective observational comparative analysis of deidentified data from inpatient adults to compare resource use and health outcomes of 1:1 propensity score matched patients who had CAVT versus embolectomy alone or with adjunctive bypass.

About Penumbra

Penumbra Inc., the world’s leading thrombectomy company, is focused on developing the most innovative technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism such as pulmonary embolism, and acute limb ischemia. Its broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe with speed, safety and simplicity. By pioneering these innovations, Penumbra supports healthcare providers, hospitals and clinics in more than 100 countries, working to improve patient outcomes and quality of life. For more information, visit www.penumbrainc.com and connect on Instagram, LinkedIn and X.

Important Safety Information

Additional information about Penumbra’s products can be located on Penumbra’s website at https://www.penumbrainc.com/products/peripheral-thrombectomy-cavt/. Caution: Federal (USA) law restricts these devices to sale by or on the order of a physician. Prior to use, please refer to Instructions for Use for complete product indications, contraindications, warnings, precautions, potential adverse events, and detailed instructions for use. Risk information can be found at peninc.info/risk.